OBJECTIVES/HYPOTHESIS: To validate a follow-up protocol based on the long-term outcomes and recurrence rates in patients who have undergone surgical treatment for olfactory neuroblastoma. METHODS: A prospective review of all patients treated for olfactory neuroblastoma at our institution over a 35-year period. RESULTS: Ninety-five patients were treated from 1978 to 2013, with craniofacial (65 patients) or endoscopic resection (30 patients). Duration of follow-up ranged from 1 to 309 months (mean, 88.66 months). Fifty-six patients were alive and well, and 13 were alive with recurrent disease. Twenty-one patients had died of disease, and three had died of intercurrent disease. Overall survival was 83.4% at 5 years and 76.1% at 10 years. Disease-free survival at 5 years was 80% and at 10 years was 62.8%. A Cox regression analysis showed orbital extension and intracranial involvement to be significant independent factors affecting outcome. Local and regional recurrence occurred after an average of 49 months but with a range of 3 to 233 months. CONCLUSIONS: In our series, olfactory neuroblastoma most commonly recurred within the first 4 years but can recur very late, after 19.4 years in one case. There is currently no universally accepted follow-up regime, but even late recurrence is eminently treatable. We therefore propose a protocol for lifelong follow-up with both clinical examination and serial imaging, including the neck and entire intracranial compartment. LEVEL OF EVIDENCE: 4.
OBJECTIVES/HYPOTHESIS: To validate a follow-up protocol based on the long-term outcomes and recurrence rates in patients who have undergone surgical treatment for olfactory neuroblastoma. METHODS: A prospective review of all patients treated for olfactory neuroblastoma at our institution over a 35-year period. RESULTS: Ninety-five patients were treated from 1978 to 2013, with craniofacial (65 patients) or endoscopic resection (30 patients). Duration of follow-up ranged from 1 to 309 months (mean, 88.66 months). Fifty-six patients were alive and well, and 13 were alive with recurrent disease. Twenty-one patients had died of disease, and three had died of intercurrent disease. Overall survival was 83.4% at 5 years and 76.1% at 10 years. Disease-free survival at 5 years was 80% and at 10 years was 62.8%. A Cox regression analysis showed orbital extension and intracranial involvement to be significant independent factors affecting outcome. Local and regional recurrence occurred after an average of 49 months but with a range of 3 to 233 months. CONCLUSIONS: In our series, olfactory neuroblastoma most commonly recurred within the first 4 years but can recur very late, after 19.4 years in one case. There is currently no universally accepted follow-up regime, but even late recurrence is eminently treatable. We therefore propose a protocol for lifelong follow-up with both clinical examination and serial imaging, including the neck and entire intracranial compartment. LEVEL OF EVIDENCE: 4.
Authors: Guillaume De Bonnecaze; B Lepage; J Rimmer; A Al Hawat; B Vairel; E Serrano; B Chaput; S Vergez Journal: Eur Arch Otorhinolaryngol Date: 2014-10-17 Impact factor: 2.503
Authors: Rohan R Joshi; Qasim Husain; Benjamin R Roman; Jennifer Cracchiolo; Yao Yu; Jillian Tsai; Julie Kang; Sean McBride; Nancy Y Lee; Luc Morris; Ian Ganly; Viviane Tabar; Marc A Cohen Journal: J Surg Oncol Date: 2018-11-22 Impact factor: 3.454
Authors: Neeraja Konuthula; Alfred M Iloreta; Brett Miles; Ryan Rhome; Umut Ozbek; Eric M Genden; Marshall Posner; Krzysztof Misiukiewicz; Satish Govindaraj; Raj Shrivastava; Vishal Gupta; Richard L Bakst Journal: Head Neck Date: 2017-08-17 Impact factor: 3.147
Authors: Victoria E Banuchi; Laura Dooley; Nancy Y Lee; David G Pfister; Sean McBride; Nadeem Riaz; Mark H Bilsky; Ian Ganly; Jatin P Shah; Dennis H Kraus; Luc G T Morris Journal: Laryngoscope Date: 2016-02-10 Impact factor: 3.325